The effect of combination therapy with Alendronate and Eldecalcitol for glucocorticoid induced osteoporosis -switch from Alfacalcidol to Eldecalcitol-

The effect of combination therapy with Alendronate and Eldecalcitol for glucocorticoid induced osteoporosis -switch from Alfacalcidol to Eldecalcitol- - The effect of combination therapy with Alendronate and Eldecalcitol for glucocorticoid induced osteoporosis -switch from Alfacalcidol to Eldecalcitol-

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009588

Enrollment

Registered

2012-12-20

Start date

2012-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glucocorticoid induced osteoporosis

Interventions

Alendronate(35mg/week)+ Alfacalcidol(1.0mcg/day) Alendronate (35mg/week) + Eldecalcitol (0.75mcg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Glucocorticoid induced osteoporosis patients who have taken Alendronate and Alfacalcidol for more than 1 year and half year, respectively. 2. Patients with informed of consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindication for Eldecalcitol treatments 2. Patients who are inappropriate for this study by physicians.

Design outcomes

Primary

Measure	Time frame
Change from baseline to 12 months in lumbar spine BMD	—

Countries

Japan

Contacts

Public ContactGoh Tsuji

Shinko Hospital Department of Rheumatic Disease

tsuji_goh@shinkohp.or.jp078-261-6711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026